Related Experiment Video

Updated: Jun 8, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines

J Wysocki1, S Tansey, E Brachet

  • 1Poznan University of Medical Sciences, Poznan, Poland.

Vaccine
|October 2, 2010
PubMed

Insights

Concomitant administration of pneumococcal conjugate vaccine (PCV7) and meningococcal C conjugate vaccine (MnCC vaccine) showed non-inferior immunogenicity and acceptable safety in infants. This combined vaccine approach offers a viable alternative for infant immunization schedules.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Pneumococcal conjugate vaccine (PCV7) and meningococcal C conjugate vaccine (MnCC vaccine) are crucial for preventing bacterial meningitis.
  • Evaluating the immunogenicity and safety of co-administering PCV7 and MnCC vaccine is important for optimizing infant immunization schedules.

Purpose of the Study:

  • To compare the immunogenicity and safety of concomitant administration of PCV7 and MnCC vaccine versus individual administration in infants.
  • To assess antibody responses to pneumococcal and meningococcal serotypes following vaccination.

Main Methods:

  • A randomized, open-label study involving three infant groups: PCV7+MnCC vaccine, PCV7 alone, and MnCC vaccine alone.
  • Vaccinations were administered at 2, 3½, 6, and 12 months for PCV7, and 2, 6, and 12 months for MnCC vaccine.
  • Immunogenicity assessed by measuring immunoglobulin G (IgG) antibody concentrations for pneumococcal serotypes and serum bactericidal assay (SBA) titres for Neisseria meningitidis serogroup C.

Main Results:

  • Non-inferior immunogenicity for PCV7 was demonstrated when co-administered with MnCC vaccine compared to PCV7 alone, with high proportions of subjects achieving protective antibody levels for all tested pneumococcal serotypes.
  • Non-inferior immunogenicity for MnCC vaccine was observed when co-administered with PCV7 compared to MnCC vaccine alone, with nearly all subjects achieving protective serogroup C meningococcal SBA titres.
  • Local reactions were similar across groups; however, the concomitant group reported higher rates of some systemic events compared to the MnCC vaccine alone group.

Conclusions:

  • Concomitant administration of PCV7 and MnCC vaccine elicited non-inferior immune responses compared to individual vaccine administration.
  • The combined vaccine regimen demonstrated an acceptable safety profile, supporting its use in infant immunization programs.
  • This study provides evidence for the feasibility of combining PCV7 and MnCC vaccines to simplify infant vaccination schedules without compromising immunogenicity.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...